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DNA SIGNAL VARIABILITY AND ITS IMPACT ON FORENSIC DNA 
INTERPRETATION AND QUANTIFICATION 
 
XIA MARIE YEARWOOD-GARCIA 
ABSTRACT 
 The increased sensitivities of recently developed polymerase chain reaction (PCR) 
and separation techniques have afforded forensic deoxyribonucleic acid (DNA) analysts 
an opportunity to detect low template deoxyribonucleic acid (LT-DNA) samples.  
However, with LT-DNA samples stochastic effects become more prevalent, compromising 
the reliability and robustness of these techniques.  In addition, these innovations have 
presented analysts with an increased incidence of higher-order mixtures.  These types of 
mixtures, confounded by LT-DNA effects, continue to test the interpretation step of the 
DNA analysis pipeline.  The combination of allele drop-out, allele drop-in and allele 
sharing create such complex samples that it necessitates the transition from traditional, 
threshold-based, interpretational methods to a probabilistic approach.  Therefore, this study 
has two objectives: 1) to optimize the computational tool NOCIt, designed to provide a 
probability distribution on the number of contributors (NOC) to a sample and 2) to 
investigate the source of the variability present in quantitative real-time polymerase chain 
reaction (qPCR) in hopes of minimizing variations observed when determining the quantity 
of an unknown DNA sample. 
 The NOCIt graphical user interface (GUI) was validated during its developmental 
phase.  With no current forensic guidelines for the validation of computational tools, the 
vii 
protocol was designed based on a guide developed by the Center for Devices and 
Radiological Health for the Food and Health Administration (FDA).  The protocol required 
using a variety of test types and detailed documentation of the methods used, the inputs, 
outputs and results.  A total of 325 tests were completed across 11 different software 
distributions.   
 As a critical software system, NOCIt’s settings also had to be optimized because of 
its ability to substantially influence the interpretation, the statistical conclusions and the 
accuracy of the results.  Two different settings (Condition 3 and Condition 4) were tested 
on AmpFlstr® Identifiler® Plus and PowerPlex® 16 HS PCR amplified samples.  The 
differences between the two conditions were the parameter Number of Samples in Batch 
and the Multiplicative Factor.  All other settings were kept the same.  The reproducibility 
and accuracy were examined to determine which condition was more reliable.  Both 
settings had similar results, with both performing better in different categories.   
 As with interpretation, quantification is an integral part of the human identification 
pipeline.  Previous studies have shown that the Quantifiler® recommended protocol of 
generating a standard curve for every quantification (referred to in this study as the 
Recommended Method) introduces additional sources of variability compared to protocols 
that utilize one, external, validated curve (referred to in this study as the Experimental 
Method).  To identify the major source of variability inherent in the quantitative 
polymerase chain reaction (qPCR) process, these two methods of determining the quantity 
of a DNA sample were investigated using the Quantifiler® Duo and Quantifiler® Trio DNA 
Quantification assays.  Four tenfold serial dilutions were quantified in five independent 
viii 
runs using the Quantifiler® Duo DNA Quantification kit and five independent runs using 
the Quantifiler® Trio DNA Quantification kit.  Quantification with Quantifiler® Duo 
reported less variability using the Experimental Method than the Recommended Method.  
Conversely, quantification with Quantifiler® Trio exhibited approximately equal 
variability between both methods.   
 To assess whether the errors associated with generating a calibration played a 
substantive role in introducing additional variability, the test samples were also quantified 
using digital polymerase chain reaction (dPCR).  The data for the more dilute samples were 
indistinguishable from the noise associated with the instrument.  The more concentrated 
samples showed less variability than the samples quantified with Quantifiler® Duo and 
approximately the same as those amplified with Quantifiler® Trio.  This suggests that both 
qPCR and dPCR processes can be used to quantify DNA amounts, however, fundamental 
differences in the ways each determines the values suggests that noise is an inherent and 
measurable part of dPCR.  Thus, for purposes of DNA quantification signal thresholds will 
need to be determined prior to implementation. 
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1.  Introduction 
1.1.  Overview 
 The discovery of hypervariable minisatellite regions of deoxyribonucleic acids 
(DNA) in the human genome was the first major milestone in the timeline of forensic DNA 
analysis.  The ability to detect genetic markers that, in combination, can be specific to an 
individual was, and continues to be, the basis for human identification (1, 2). 
Since this discovery, the use of minisatellite regions of DNA has transitioned to the 
use of short tandem repeat (STR) markers for human identification.  These markers are 
generally repeat units of two to five base pairs (bp) that are present in various locations in 
the human genome (3, 4).  The STR typing process that is currently used begins with the 
extraction of the DNA from cellular material (5).  After the nucleic acids are isolated, the 
amount of human DNA is determined to ensure the optimal template is used in downstream 
assays.  This is usually achieved via quantitative real-time polymerase chain reaction 
(qPCR)(6).  The target mass of DNA is then amplified using polymerase chain reaction 
(PCR).  Amplification involves the synthesis of copies of short fragments of the DNA 
templates, such that they may easily be detected (7, 8).  Multiplex PCR is used to 
simultaneously amplify more than one region of DNA(9, 10).  The end product of this type 
of PCR is a mixture of various DNA molecules of different fragment sizes that must be 
distinguished.  These fragments are separated by capillary electrophoresis (CE) (11, 12).  
The output that results from the CE is an electropherogram (EPG), which is a graphical 
display of the DNA fragments as depicted by a series of peaks labeled with their allele call, 
size in bp and quantity in relative fluorescent units (RFU) (13).  Once analyzed, the DNA 
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profile is in a form that can be interpreted.  Interpretation includes the comparison of the 
evidentiary data to known genotypes in order to determine if a person of interest (POI) is 
a likely contributor to the sample (14).   
The recommended template mass for STR amplification is currently 200 pg to 2 ng 
of DNA (10, 15).  However, frequently the forensic DNA laboratory processes samples 
that contain only a few copies of DNA.  This is known as low-template (LT-) analysis (16).  
The ability to detect low-template DNA has greatly improved as a result of  modifications 
to the laboratory parameters such as increasing the PCR cycle number (17), post-PCR 
purification (18), the use of  highly deionized formamide during the CE setup (19), and 
increased CE injection time (20).  In addition, the forensic DNA instruments and assays 
have also become more sensitive, allowing for the analysis of lower template DNA samples 
(21, 22) . 
Despite the numerous judicial advantages of being able to analyze low-template 
samples, there are some drawbacks.  For example, low-template DNA samples are prone 
to stochastic effects, which introduce the potential for error during interpretation because 
allele drop-out, allele drop-in, peak height imbalance and larger than normal stutter peaks 
(17, 23, 24) confound the signal.  DNA inference becomes even more complicated when 
many low-template contributors comprise the sample.   
To keep abreast of the field as it progresses into the realm of interpretation of 
multisource LT-DNA samples, researchers must ensure that protocols are continuously 
quality checked, sources of unreliability and variability are met with quality control 
procedures, and that new forensic tools are properly validated for optimal results.  In trying 
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to work towards this, the work described below seeks to optimize the use of a 
computational tool for determining the number of contributors (NOC) to a sample by 
performing software validation.  In addition, a preliminary investigation into the variability 
observed during the quantitation step of the DNA analysis pipeline was conducted, with 
the intent of characterizing and minimizing the sources of variability.   
1.2.  DNA Interpretation 
1.2.1.  Methods of Interpretation   
 DNA interpretation begins with the use of a genotyping software through which 
users acquire the sizes of alleles at forensically relevant short tandem repeat (STR) loci 
(13).  The Federal DNA Advisory Board (DAB) suggests that forensic casework reports 
include results and/or conclusions (25), which may contain a statement regarding the 
minimum NOC from which the sample in question could have arose.  This can be done 
using a several approaches, based on allele counting methods, such as Maximum Allele 
Count (MAC) (26) and Total Allele Count (27).  Alternatively, probabilistic approaches 
like Maximum Likelihood Estimator (MLE) (28) and Bayesian approaches (29) can also 
be utilized.  However, stochastic effects, such as allele drop-out, allele drop-in and allele 
sharing, affect the NOC, especially when ability to accurately and specifically infer the 
NOC, especially when dealing with samples with multiple DNA contributors and low-
template amounts (30). 
1.2.2.  NOCIt 
 Due to the limitations of current methods to determine the NOC of a DNA sample, 
a unique opportunity presented itself for the development of an alternative that could better 
4 
account for the large variability observed in forensic DNA profiles.  As such, NOCIt was 
created to fulfill this purpose. 
 NOCIt, based on the foundational work of Swaminathan et al., is a computational 
tool that calculates the a posteriori probability (APP) that one, two, three, four and five 
contributors gave rise to the unknown DNA sample in question.  NOCIt functions by 
interpreting the autosomal STR signal, the stutter (both forward and reverse) signal and 
baseline noise.  Using a Monte Carlo (MC) sampling process, NOCIt determines the 
likelihood that n unrelated individuals contributed to a sample.  During the MC process, 
genotypes for the n contributors are chosen based on the allele frequencies provided, and 
the ratio of the n contributors to the mixture is selected from a uniform distribution.  Peak 
height information, which is generated by examining known single-source calibration files, 
is used to determine the likelihood of observing the peak heights at each locus given the 
genotypes of the contributors and the category (i.e.  allele, stutter and noise).  Allele drop-
out rates and differential degradation are also modeled and simulated (31).   
 The work of Swaminathan et al.  using version 1.5.1 of NOCIt demonstrated that it 
was able to outperform methods like MLE and MAC when determining the NOC of both 
experimental and simulated samples.  Using samples ranging from one to five contributors, 
NOCIt yielded the highest accuracies across all three methods, correctly identifying the 
true number of contributors (NOCtrue) approximately 10% better than the other methods.  
Additionally, the true NOC was assigned at least a 1% APP in 95% of the samples tested 
using NOCIt (32). 
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 With version 1.5.1 showing promising results, version 3.1 was developed.  This 
updated version has a more extensive and user-friendly graphical user interface (GUI) as 
well as additional functions, modules and models.  Prior to completing any studies on 
version 3.1, the software tool was tested, verified and validated. 
1.2.3.  Software Validation 
 Validation is establishing, through documented experimentation, that a scientific 
method or technique is fit for its intended purpose (33).  According to SWGDAM 
validation guidelines and definitions, two types of validations are required prior to 
implementing a new technology for forensic DNA analysis: 1) developmental and 2) 
internal.  The developmental validation involves optimization of the accuracy, precision 
and reproducibility of the technology.  Specifically, for probabilistic tools, the data 
acquired throughout this process should verify the functionality of the system, determine 
the appropriateness of the statistical parameters, assess the accuracy of the calculations and 
results and identify potential limitations.  This validation is completed by the manufacturers 
or developers of the software.  Once the equipment is brought into a forensic DNA testing 
laboratory for use, an internal validation is to be conducted.  This is completed, in-house, 
to investigate its reliability and limitations, which could differ between laboratories.  In 
particular, this testing would determine laboratory-specific settings and parameters and 
ensure that the algorithms and models performed optimally and as expected (34, 35).   
Following initial release, updated versions of a given software are typically issued 
with new features and bug fixes.  However, as the software continues to evolve, additions 
and changes to its original design can be a source of new defects.  These errors are 
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frequently unanticipated and can cause significant disruption.  Therefore, because of the 
complexities of software, the validation must be tightly controlled and requires significant 
managerial scrutiny (36). 
There are general principles that should be considered when validating software.  
First, software requirements must be specified and documented to provide a baseline for 
validation.  Also important is the quality assurance (QA) of the software.  The main focus 
of QA should be defect prevention, particularly because the complexities of software 
render it difficult to detect all errors present in the source code during routine testing.  
Therefore, a great amount of time and effort has to be put into the testing process as well 
as its planning, development and documentation.  The procedures used during the testing 
process should identify the specific sequence of actions taken to complete all validation 
activities and should include the steps taken after a change is made: notably, in addition to 
validating the change, the validation status of the entire software has to be re-established.  
Lastly, developers and testing teams should ensure that the software is robust and 
applicable in a wide spectrum of environments during design, development and validation 
(36). 
 Though scientific validation is commonplace within forensic laboratories, software 
validation is not yet a standard practice; therefore, the standard operating procedure used 
for software validation of NOCIt was developed according to the recommendations 
published in (36).  The validation strategy, and therefore the extent of the testing, ultimately 
depends on the criticality and complexity of the software (37); that is, the validation scheme 
requires that the software be categorized as critical/not critical and complex/not complex.  
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For purposes of this work, NOCIt was characterized as critical, because of its potential to 
substantially influence the interpretation, statistical conclusions and accuracy of the results 
and complex, because it executes many lines of code and is comprised of interconnecting 
modules.   
 The characterization of NOCIt as both critical and complex required three test types 
to be conducted during validation: 1) reliability, 2) regression and 3) functional testing.  
Reliability testing checks beyond the functional aspects to measure the reliability of the 
software in the laboratory environment.  This includes testing the impact on software 
performance when used by multiple individuals or implemented in multi-site scenarios and 
verifying that network, server and other applicable resources can handle the application's 
needs.  Regression testing confirms that changes or new functionalities do not unacceptably 
alter or terminate a desired functionality that behaved correctly before the change was 
implemented.  Functional testing confirms that the software performs tasks as expected.  
There are four sub-types of functional tests: 1) positive, 2) negative, 3) fuzz and 4) 
boundary tests.  Positive tests confirm that the natural (or usual) inputs yield the expected 
output.  Negative tests confirm that incorrect or inverse inputs yield the expected output.  
Fuzz tests confirm that invalid, unexpected or nonsensical inputs to a computer program or 
module yield an acceptable response.  Boundary tests confirm expected outputs are 
obtained when inputs are at the limits of the software (38).  Several of each of these types 
of tests were completed during developmental validation to ensure proper functioning of 
NOCIt. 
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Validation of NOCIt in this study is developmental, as it was tested for distribution 
by the developers and the testing team, and also internal, because the NOCIt parameters 
were optimized to yield the best in-house results.  As recommended by SWGDAM, the 
testing was done with data generated in-house that were representative of the 
amplifications kits, detection instruments and genotyping software used in the laboratory 
(35).   
Once the NOCIt graphical user interface (GUI) was validated, its settings were also 
validated to ensure that the NOCIt results are reproducible, reliable and timely.  The NOCIt 
settings that were tested are described below: 
“Levels for Mixture Ratios: the number of evenly spaced discretization levels used 
for mixture ratios.  For example, if there are 16 levels, then a contributor in a 
mixture can contribute any fraction i/16 of the DNA of the sample, where i is an 
integer greater than or equal to 1 and less than or equal to 16.  The larger the value 
for this setting, the longer NOCIt will run but the more accurate its results will be 
in theory” (31).   
“Standard Error Tolerance: the tolerance level on the estimated standard error of 
the a posteriori probability distribution used for termination.  NOCIt first performs 
an initial MC sampling for each number of contributors from 0 to the maximum 
number of contributors.  After this initial sampling, NOCIt selectively performs 
more MC sampling until either (1) the estimated standard error of the a posterior 
probability for all numbers of contributors is below this setting, or (2) the running 
time exceeds the refinement time limit” (31).   
“Refinement Time Limit: the time limit applied during the refinement phase, after 
the initial MC sampling is complete” (31). 
“Number of Samples in Batch for NOC = 1: number of MC samples used at each 
locus during the initial MC for the number of contributors set to 1” (31).   
“Multiplicative Factor: the multiplicative factor is used to determine the number of 
MC samples used at each locus during the initial MC sampling for numbers of 
contributors greater than 1.  The multiplicative factor is applied each time the 
number of contributors is increased by 1” (31).   
Maximum Number of Samples in a Batch: the maximum number of MC samples 
used at each locus during the initial MC sampling for any number of contributors” 
(31). 
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Changes to these settings affect NOCIt’s accuracy, reproducibility and analysis 
time.  Ultimately, the ideal combination of settings will produce results that are accurate 
and reproducible and reached within a practical time frame.   
1.3.  DNA Quantitation  
 The purpose of determining the amount of DNA in a sample is to identify the 
optimal volume of extract that ought to be added to the STR multiplex PCR reaction.  
Adding too much DNA could saturate the detector, while adding too little can result in 
stochastic effects.  The ideal amount of DNA would result in the detection of all alleles, 
such that heterozygous loci exhibit good peak height balances and a significant proportion 
of the peaks are not off-scale (39).  For these reasons, the accurate quantification of DNA 
in the extract is of importance.  Therefore, when it was demonstrated that there was an 
increase in variability when repeatedly creating a calibration curve for each qPCR run, it 
became prudent to determine the source of that variability so as to improve the 
reproducibility of the quantification step (40). 
1.3.1.  Quantitative Real-Time Polymerase Chain Reaction 
 A common approach for quantifying unknowns is by utilization of a TaqMan® 
probe, which is a method by which the formation of PCR product is monitored by reporting 
the growth in fluorescence at every PCR cycle.  Specifically, this approach involves the 
hybridization of a probe to a location of interest on the DNA.  The probe has a reporter dye 
attached to its 5’ end and a nonfluorescent quencher at the 3’ end.  When the fluorophores 
are in close proximity, the fluorescence of the reporter dye is suppressed by the quencher.  
However, during PCR extension, polymerization of a new strand occurs and the 5’ 
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exonuclease activity of Taq polymerase degrades the probe, resulting in separation of the 
reporter and quencher such that an increase in fluorescent signal may be detected as more 
DNA fragments are synthesized throughout PCR cycling (41). 
 One may estimate the starting copy number of DNA by recording the number of 
cycles required for fluorescence to cross the pre-determined signal threshold, where more 
concentrated samples would reach the signal threshold at earlier cycle numbers.  Thus, 
through the use of a standard dilution series and a plot of the log of the concentration versus 
the cycle threshold, the concentration of the unknown sample can be estimated (39).   
 For the purposes of this study, both the Applied Biosystems Quantifiler® Duo (QD) 
and Quantifiler® Trio (QT) Quantification Kits (Applied Biosystems, Foster City, CA) 
were employed.  Quantifiler® Duo simultaneously amplifies a single copy human locus, 
human Ribonuclease P RNA Component H1 (RPPH1), a male sex determining Y (SRY) 
region and an internal positive control (IPC), which is a synthetic sequence not found in 
nature.  Human pooled male genomic DNA is used to generate the DNA quantitation 
standard dilution series.  The manufacturer of the QD assay recommends eight dilutions 
ranging from 50 to 0.23 ng/µL (42). 
 The QT assay simultaneously amplifies two human autosomal regions: a small 80 
bp target sequence and a large 214 bp target sequence.  Both sequences are multicopy and 
located in several locations in the genome.  Similar to the QD assay, a Y chromosome 
target and an IPC are co-amplified with the autosomal targets.  Human pooled male 
genomic DNA is used to generate the DNA quantitation standard dilution series wherein 
five dilutions ranging from 50 to 0.06 ng/µL are recommended (22). 
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1.3.2.  Digital Polymerase Chain Reaction 
 Though PCR is the mainstay technique for absolute quantification in forensic DNA 
laboratories (43, 44), it is only one of a few analytical methods that are effective in 
quantifying DNA.  One alternative method to qPCR is digital PCR (dPCR).  Despite its 
widespread use in clinical applications (45-48), it has yet to find its way into forensic 
laboratories.  There are many versions of dPCR systems available (45, 49-51).  In this 
work, we focus on the QuantStudio™ 3D Digital PCR system (52-56).   
The dPCR setup is similar to the qPCR setup in many attributes as it is also a 
TaqMan® probe-based assay.  The main difference is the time point at which the fluorescent 
measurement is recorded, where qPCR is monitored in real-time and dPCR is end-point 
based.  Specifically, the dPCR reaction mix is prepared by adding an aliquot of sample, 
primers, TaqMan® probe and PCR reaction reagents.  The sample and dPCR master mix 
are loaded on a chip containing 20,000 755 pL wells.  As the sample is loaded onto the 
chip, small aliquots, containing one copy of template molecule, settle into the pico-wells.  
The chips are loaded onto a flat block thermalcycler for amplification.  Due to the design 
of the chip, each of the 20,000 wells undergoes an independent PCR amplification (52).  
After PCR, the chips are imaged, and the number of wells with signal exceeding baseline 
are counted and represent the concentration of DNA in the extract (57)  
Research indicates that the use of a validated external historic calibration curve is 
robust and gives more reproducible results (40).  This variability usually sources from the 
propagation of error that occurs when creating a dilution series and accumulates from the 
highest to the lowest concentration (58).  Therefore, when a dilution series is created during 
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the generation of a calibration, the intent is to establish a concentration-response 
relationship fitted to that data and then use that relationship to predict the concentration of 
an unknown.  However, Higgins et al.  demonstrated that if the random measurement error 
that results from the dilutions is not accounted for, the consequence can be critical 
inaccuracies in the assay precision (59).  As recommended by manufacturers of the QT and 
QD assays (60, 61), it has been shown that generating a duplicate calibration curve and 
using the average of the curves improves the precision of the assay (62).  However, with 
using this method, there still appears to be a significant source of variability in using the 
QD qPCR assay (40).  Given the reliance of qPCR on external calibrators generated by the 
production of a dilution series and the propagation of error associated with such series, 
evaluating a method such as dPCR, that does not rely on external calibrators, is of interest.   
Additionally, studies have shown that dPCR outperforms qPCR in sensitivity, 
precision and susceptibility to inhibitors (63-66).  As such, dPCR may be useful asset in 
forensic settings which frequently test LT (67), inhibited (68) and degraded samples (69). 
In summary, this study examines the accuracy and precision of two qPCR assays 
and one dPCR assay.  Specifically, the ability to quantify a set of samples containing a 
range of concentrations from 0.5 to 0.0005 ng/µL will be tested.  The accuracy will be 
interpreted by comparing the measured value against the nominal value, while the precision 
is explored by assessing the coefficient of variation across concentrations.  Further, 
concordance between the bioanalytical techniques will be explored.  Other metrics, such 
as the dynamic range, of each system, will be discussed. 
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2.  NOCIt Optimization 
2.1.  NOCIt Setup 
 NOCIt analysis is a two-step process involving the creation of a calibration project 
followed by the analysis of an unknown DNA sample.  On the NOCIt GUI, these processes 
are separated into different tabs.  Both tabs require the input of a series of correctly 
formatted tab-delimited text (TXT) and comma-separated values (CSV) files for accurate 
functioning of the tool.  Therefore, prior to beginning any analyses using NOCIt, the 
required input files were created for each tab.   
2.1.1.  Calibrate Tab Requirements 
 The calibration tab required two different input files: a kit file and a calibration file.  
A known genotypes file, though not required, was also recommended.  All three files were 
kit-specific; therefore, each file had AmpFlstr® Identifiler® Plus (Life Technologies, 
Carlsbad, CA) (70, 71), GlobalFiler® (Life Technologies, Carlsbad, CA) (72, 73) and 
PowerPlex® 16 HS (Promega Corporation, Madison, WI) (74, 75) versions.   
2.1.1.1.  Kit File 
The kit file defined the loci that were to be analyzed by NOCIt.  It included the loci, 
the color of the fluorescent dye with which each locus was labeled, and all the common 
allele calls and their corresponding bp sizes.  The kit file was exported from GeneMapper®® 
ID-X and saved as a TXT file.  Its format is depicted in Figure 1. 
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Figure 1.  NOCIt kit file format.  The second line of the document lists the chemistry kit 
used to amplify the samples.  In this example, Identifiler Plus® was used.  The third line 
has the name of the STR locus (i.e., marker) and its corresponding dye colour.  Below 
each marker name, the common allele calls associated with that marker are listed in 
numerical order.  Adjacent to each allele call is its size in bp. 
 
2.1.1.2.  Calibration File 
The calibration files, as depicted in Figure 2, consists of a series of known single-
source samples produced and analyzed using the same standard operating procedures as 
the unknown evidentiary samples.  These samples were created using various template 
masses, dilutions and multiple quantification, amplification, and capillary lot numbers.  
Since NOCIt was also used to analyze degraded samples, some of the samples were 
compromised to various degrees to capture as much signal variety as possible.  The 
electropherograms for these samples were analyzed at 1 RFU on GeneMapper® ID-X to 
allow for baseline noise to be evaluated later by NOCIt.  Dissociated dye and spikes were 
the only artifacts manually removed.  The remaining data were exported from the 
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genotyping software, saved as CSV files and compiled.  These files contained tabularized 
data from the EPG, such as the allele call, height and size information for all peaks detected 
at the loci tested.   
 
Figure 2.  NOCIt calibration file format.  The first column lists the sample file name 
which describes the sample.  The second column lists the STR loci associated with the 
STR amplification kit used.  This example lists the 16 loci tested with Identifiler® Plus.  
The dyes are listed in the third column: blue (B), green (G), yellow (Y) and red (R).  The 
following columns list each allele call, its size in bp and its height in RFU, grouped in 
that order. 
 
The first row of the calibration files was the header line.  The first column labeled 
“Sample File” contained the sample file names.  These names included general information 
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about the sample, including the template mass and the known contributor.  Each STR locus 
is listed under the “Marker” column, and the fluorescent color associated with that marker 
was listed in the “Dye” column.  The dyes were referred to by the first letter of their 
respective color: B is blue; G is green; Y is yellow and R is red.  The following columns 
included the allele, size and height for every peak that appeared at that locus. 
2.1.1.3.  Known Genotypes File 
The final file that was created was the known genotypes file, which was also saved 
as a CSV file.  This file is depicted in Figure 3.  The file specifies the genotypes of the 
donors from which the single-source calibration file samples were obtained.  This file could 
have been created using the NOCIt interface; however, unless this “genotype-building” 
function was being tested, this file was created in Excel and imported into the GUI. 
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Figure 3.  NOCIt known genotypes file format.  Each row describes the known genotype 
of a donor.  The first column lists the identification used to refer to the known genotypes.  
The knowns in this study were assigned sequential numerical identifiers.  The genotypes 
at each STR locus are listed in the following columns.   
 
The first row of the known genotypes file was the header line.  The first column, 
entitled “Sample ID,” contained a unique identifier for each source used to create the 
calibration files.  For this study, the cell types were assigned numerical IDs.  The other 
columns list every marker present in the calibration files.  The cell type’s known genotype 
at each locus was listed separated by commas.  When homozygous at a particular location, 
the allele was listed twice and was also separated by commas.   
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2.1.2.  Calibrate Tab 
All the files specified in Section 2.1.1 were imported into the Calibrate tab, depicted 
below in Figure 4.  The calibration project was assigned a name in the first input box.  The 
kit file, exported from GeneMapper® ID-X, was imported into the box designated “Kit” 
and the folder containing the calibration files was imported into the box designated “Load 
Calibration File(s).” All the samples in the calibration file were listed in the “Calibration 
Data” table highlighted in Figure 4.   
 
Figure 4.  NOCIt Calibrate tab.  Inputs are imported into the top half of the Calibrate 
tab.  A name is assigned to the calibration project by typing it into the input box next to 
“Calibration Name.” The kit file is imported in the following input box.  The calibration 
file is imported into the third import box.  The table below “Calibration Data” lists the 
samples in calibration files.  Each calibration sample can be filtered to remove certain 
artifacts typically present in the EPG by checking the boxes in the “Filter” column.  The 
known genotypes are assigned to each sample under the “Known Genotypes” column. 
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NOCIt has the ability to remove pull-up, complex pull-up and minus A artifacts 
from the calibration sample files using an automated filter function.  This function is 
controlled by various user defined parameters.  The settings listed in Table 1 were utilized: 
 
Table 1.  Description of NOCIt filter settings used during the validation and 
reproducibility studies.   
Artifact Example Filter Parameter 
Setting 
Utilized 
Example 
Calculation 
Pull - up 
	
 
Pull-up 
Height Ratio 
 
6 % 
5	𝑅𝐹𝑈500	𝑅𝐹𝑈 
Pull-up Size 
Range 
 
0.6 bp 99.7 bp < pull-up peak < 100.9 bp 
Complex 
Pull-up 
	
 
Complex 
Pull-up 
Height Ratio 
 
6 % 
5	𝑅𝐹𝑈500	𝑅𝐹𝑈 
Complex 
Pull-up 
Sister Height 
Ratio 
 
50 % 
500	𝑅𝐹𝑈505	𝑅𝐹𝑈 
Complex 
Pull-up Size 
Range 
 
0.3 bp 
99.7 bp < complex 
pull-up peak < 
104.3 bp 
Minus A 
 Minus A 
Height Ratio 
 
16.7 % 
50	𝑅𝐹𝑈500	𝑅𝐹𝑈 
Minus A 
Size Range 
 
0.6 bp 99.7 bp < minus A peak < 100.9 bp 
 
Pull-up is the result of colour bleeding from one spectral channel into another.  Peak 
signal is carried over to adjacent colour channels because of improper separation of spectral 
100.3 bp 
500 RFU 
100 bp 
5 RFU 
Allele 1 
100 bp 
500 RFU 
  102 bp 
  5 RFU 
Allele 2 
104 bp 
505 RFU 
 100.3 bp 
 500 RFU 
100 bp 
50 RFU 
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overlap of the dyes used for STR allelic detection (76).  The height ratio is calculated by 
dividing the pull-up peak height by its parent peak height.  The Pull-up Height Ratio is the 
maximum allowable value of this ratio.  The Pull-up Size Range is the largest sizing 
difference between the pull-up and parent peaks.  A peak is designated as pull-up and 
removed from calibration/sample files by NOCIt if 1) the pull-up peak and the parent peak 
are labeled with different dyes, 2) the ratio of the pull-up peak height and the parent peak 
height falls below the Pull-up Height Ratio and 3) the pull-up bp size is within +/- the Pull-
up Size Range from the parent peak bp size (31). 
Complex Pull-up occurs when a locus is heterozygous and the two peaks are within 
one repeat unit of each other.  In certain genotyping software, this can cause a single 
plateau-shaped peak to be observed in another colour channel (77).  The height ratio is 
calculated by dividing the pull-up peak height by the shorter of the two sister parent peak 
heights.  The Complex Pull-up Height Ratio parameter is the maximum allowable value of 
this ratio.  The sister height ratio is calculated by dividing the the peak heights of the two 
sister alleles.  The Complex Pull-up Sister Height Ratio parameter is the minimum 
acceptable value of this ratio.  The Complex Pull-up Size Range is the largest sizing 
difference between the pull-up and parent peaks.  A peak is designated as complex pull-up 
and removed from calibration/sample files by NOCIt if 1) there are two sister alleles at the 
same locus and one repeat apart, 2) the ratio of the sister alleles’ heights are at least equal 
to the Complex Pull-up Sister Height Ratio, 3) the pull-up peak and the parent peaks are 
labeled with different dyes, 4) the ratio of the pull-up peak height and the smaller parent 
peak height falls below the Complex Pull-up Height Ratio and 5) the pull-up bp size is 
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between - the Complex Pull-up Size Range of the smaller parent peak and + the Complex 
Pull-up Size Range of the larger parent peak (31). 
A general property of DNA polymerase is the addition of a non-template adenine 
(A) to the end of the target sequence (78).  PCR amplification can be engineered to 
incorporate primer sequences which promote the addition of the A (plus A).  This, however, 
is not 100% efficient and can result in sequences without the additional non-template A 
(79), referred to as minus A.  The height ratio is calculated by dividing the minus A peak 
height by the plus A peak height.  The Minus A Height Ratio parameter is the maximum 
allowable value of this ratio.  The Minus A Size Range is the largest sizing difference 
between the minus A and plus A peaks.  A peak is designated as minus A and removed 
from calibration/sample files by NOCIt if 1) the ratio of its height and the plus A height 
falls below the Minus A Height Ratio and 2) the minus A bp size is within +/- the Minus 
A Size Range from the plus A bp size (31). 
After importing the calibration files, the filter option was selected for all samples.  
Pull-up, complex pull-up and minus A were removed from the signal data of the calibration 
files based on the filter settings.   
The known genotypes file was imported using the “Import Known Genotypes” 
option located in the “File” tab on the top left of the GUI.  Once the file was imported, the 
genotypes were either assigned to each sample automatically by manipulating the General 
Settings or manually assigned by selecting the genotype from the drop-down box under the 
“Known Genotype” column next to each sample.  All files had to have a genotype 
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assignment before proceeding.  Unless validating the manual method, the known genotypes 
were always automatically assigned.   
On the second page of the Calibrate tab, the parameters for the calibration were 
calculated by using the “Calculate” button.  Graphs for each parameter at every locus were 
displayed on the right by selecting the parameter and locus of interest on the left, as shown 
in Figure 5.  The graphs plot peak height (in RFU) versus an independent variable that 
varied between the parameters.  Each blue dot represented a different data point, and the 
red line represented the model for that parameter.  The green and blue lines represented ± 
1 standard deviation (SD) of the model, respectively.   
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Figure 5.  The second page of NOCIt Calibrate tab.  The left portion of this page lists 
the locus specific models for the peak height, stutter and noise parameters.  The 
parameters are listed in the first column.  The formula for each locus at each parameter 
is listed in the second column.  The values to complete the models are listed in the 
columns ‘a’, ‘b’, ‘c’ and ‘d’.  The graph on the right side of the page corresponds to the 
highlighted locus for the “Allele Peak” parameter.   are the data points used to calculate 
the model.  ⎯  depicts the model.  ⎯ and ⎯ are ± 1SD from the model. 
 
2.1.3.  NOCIt Tab Requirements 
Sample file analysis occurred on the NOCIt tab.  The user had to provide the 
required input files, select particular settings and activate/deactivate several functions in 
order to proceed to analysis.  Similar to the Calibrate tab requirements, the input files for 
the NOCIt tab were kit-specific; therefore, each file had AmpFlstr® Identifiler® Plus, 
GlobalFiler® and PowerPlex® 16 HS versions.  The formats of the input files and 
descriptions of the settings are delineated below.   
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2.1.3.1.  Populations  
Before sample files were analyzed, at least one population had to be created which 
specified the frequency with which the alleles at a given locus were observed in the 
population of interest.  In this study, allele frequency data were specific to the STR 
amplification kit used and were obtained from the manufacturers.  African American, 
Caucasian and Hispanic populations were used for each STR amplification kit used.  To 
create a population, an allele frequency file, depicted in Figure 6, was imported. 
 
Figure 6.  NOCIt frequency file format.  The first column, “Locus,” lists the STR loci.  
The second column, “Allele,” lists the alleles at that locus, and their observed frequencies 
in the population are listed in the following column, “Frequency.” Alleles with no known 
frequency are left blank.  The data in this file were obtained from (70). 
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 The allele frequency file was a CSV formatted file that was created manually from 
the data attained in (70).  The first row was the header line that listed the locus, the alleles 
present in the population at that locus and the frequencies of those respective alleles.  All 
loci listed in the frequency file were concordant with the kit file. 
 Populations were created by importing the allele frequency file for the population 
of interest into the “Population Manager” window in the View tab, as shown in Figure 7. 
 
Figure 7.  Adding population data to NOCIt using the Population Manger.  This window 
requires the input of a population name, the import of the frequency file and the input of 
the number of people used in the study to create the frequency data. 
 
 Populations also required population names and the number of people from which 
the allele frequency data were obtained.  The population names usually included the 
population and some description as to the source of the frequency data.   
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2.1.3.2.  Calibration Projects 
 The calibration project was the file created in the Calibrate tab.  This file was 
created and saved prior to analyzing any samples in the NOCIt tab.  Since numerous STR 
amplification kits were tested, a calibration was created for each kit. 
2.1.3.3.  Output Folder 
 In NOCIt, the user must designate a location for the various output files, such as 
the PDF report.  For each sample analyzed in NOCIt, a PDF report was generated when 
the analysis was complete which provided the computed probability and log likelihood 
distributions on the NOC.  In addition to the results of the analysis, the PDF report 
summarized the various input files, the filter settings used and the locus-specific analytical 
thresholds (ATs).  A graphical representation of the probabilities versus the NOC was also 
included in the report.  Figure 8 is an example of the PDF report. 
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Figure 8.  NOCIt PDF report.  The report begins by listing the user, as well as the date 
and time that the report was created.  It also includes the files imported/selected for the 
analysis and the files used to create the calibration project.  The locus-specific analytical 
thresholds are then listed under the heading “Analytical Thresholds.” The probability 
distribution on the NOC (from zero to the maximum number of contributors) is listed 
along with the corresponding log likelihood.  The probability distribution is also 
portrayed as a bar graph at the end of the report. 
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 Another output automatically created by NOCIt was the “Data Analyzed” file.  It 
was a CSV output produced for each sample analyzed.  The file represented the exact EPG 
signal analyzed by NOCIt.  Therefore, all off-ladder (OL) peaks, off-marker alleles, 
artifacts that fulfilled the filter function criteria and all signal that fell below the applied 
AT were removed.  The “Data Analyzed” file format was identical to the sample file as 
shown below in Figure 9 and represents the signal that is utilized during interpretation.   
 
Figure 9.  NOCIt Data Analyzed file.  The first column lists the sample file name which 
describes the sample.  The second column lists the STR loci tested.  This example lists 
some of the 24 locations associated with GlobalFiler®.  The following columns listed 
each allele call, its size in bp and its height in RFU, grouped in that order. 
 
2.1.3.4.  Include Results as CSV 
This was another output created by NOCIt, depicted in Figure 10.  In addition to 
creating a PDF report for each sample file analyzed, the results of all analyzed sample files 
were also compiled into one CSV file.  It is especially useful for the in-house validation of 
the software or for research purposes.  This output was not automatically produced but 
created if “Include Results as CSV” was checked.  If selected, a name and a location for 
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the file was designated.  Every sample file analyzed by NOCIt always had a corresponding 
PDF report which summarized the results of analysis of that sample; selecting this option 
did not override the PDF report outputs.  Similar to the PDF report, the “Include Results 
as CSV” option also listed all the input files used during the analysis as well as the all the 
general, filter and NOCIt settings applied. 
 
Figure 10.  NOCIt Results as CSV output.  This output combines the results of all the 
sample files analyzed together into one document.  It lists the directory of the output 
files, the sample name and any comments or case numbers associated with the sample, 
the input file data for both the NOCIt and Calibration tabs, the settings used at the time 
of analysis and the probability distribution results for each sample. 
 
2.1.3.5.  Maximum Number of Contributors  
The maximum number of contributors (NOCmax) represented the maximum number 
of individuals for which the user was interested in computing the a posteriori probability.  
Values included any integer between 1 and 5, which were selected from a dropdown menu 
prior to testing.  The time taken for NOCIt to complete its analysis was dependent on the 
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option chosen.  The smaller the NOCmax, the shorter the time taken for NOCIt to complete 
its analysis.   
2.1.3.6.  Filter Function 
 Similar to the filter function on the Calibrate tab, sample files could be filtered for 
pull-up, complex pull-up and minus A by selecting the filter function on the NOCIt tab.  
All samples in this study were either filtered using the NOCIt filter function or manually 
filtered.   
2.1.3.7.  Sample Files 
The sample file(s) were the unknown or test files containing allelic signal which 
were to be analyzed in NOCIt to determine the NOC.  It was a CSV file of the 
electropherogram signal analyzed and exported from GeneMapper® ID-X in the same way 
as the calibration file.  Figure 11 shows an example of a sample file. 
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Figure 11.  NOCIt sample file format.  The first column lists the sample file name which 
describes the sample.  The second column lists the STR loci associated with the STR 
amplification kit used.  This example lists some of the 16 locations associated with 
Powerplex®16 HS.  The dyes were listed in the third column using B for blue, G for 
green, Y for yellow and R for red.  The following columns listed each allele call, its size 
in bp and its height in RFU, grouped in that order.   
 
The first line of the sample file was a header line.  The first column was the “Sample 
File” column, which contained a unique identifier for each test file.  This is because one 
sample file contained information from one or more samples for simultaneous import of 
several samples at once.  NOCIt was able to use the information in this column to recognize 
the number of different test samples in the file.  The second and third columns were 
“Marker” and “Dye,” respectively.  These columns were identical to those specified in the 
kit file used to create the calibration.  The following columns included the allele, size and 
height for every peak at that locus, in that order.  Only alleles with numeric allele calls 
were considered by NOCIt (i.e., alphabetic characters such “OL” or “OMR” were ignored). 
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2.1.3.8.  Analytical Thresholds 
 Locus specific analytical thresholds (ATs) could be applied to the sample files by 
clicking the “Analytical Thresholds” button.  The Analytical Thresholds window (Figure 
12) lists all the common loci between the calibration projects and sample files, and their 
respective ATs.  Each locus had a default setting of 1 RFU until it was saved as otherwise.   
 
 
Figure 12.  NOCIt analytical thresholds window.  The first column lists the loci that are 
concordant with the calibration project.  The values in the “Threshold” column are the 
analytical thresholds (in RFU) to be applied at the given locus.   
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2.1.4.  NOCIt Tab 
 To begin adding samples, the “+” button on the NOCIt tab was selected which 
opened the “Add Batch Run” window shown in Figure 13.  It was in this window that all 
the input files were imported and criteria for the analysis was selected.   
 
Figure 13.  NOCIt “Add Batch Run” window.  The calibration project, output options, 
NOCmax, filter option and populations can be chosen on the right side of the window.  On 
the left, the sample files can be imported.  The samples are then listed in the empty space.  
When the samples are uploaded, an option for setting the analytical thresholds appears. 
 
 Once all the data in this window was deemed appropriate, the samples were added 
to the NOCIt tab.  The samples appeared in the NOCIt window, depicted in Figure 14.  In 
this window, all the files and criteria selected in the “Add Batch Run” window could be 
manipulated.  However, these functions were avoided unless they were being validated.   
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Figure 14.  NOCIt tab.  After the batch is added, the samples are listed in the table in the 
NOCIt tab.  The first column is the graph option that, if selected, will display the graph 
of the probability distribution for the sample.  The second column, “Case #,” can be 
edited to include a case number associated with the sample.  The sample name is listed 
in the third column, “Sample.” The option to filer can be edited in the “Filter” column.  
The population selected when adding the sample is listed in the “Population” column.  
The “Max NOC” is the maximum number of contributors chosen.  The calibration 
project and the location where the output file will be saved are listed in the “Calibration” 
and “Output” columns, respectively.  The “Comments” column can be used to type in 
any string.  The progress of the analysis can be tracked in the rectangular bar between 
“Cancel” and “Time Elapsed.” 
 
NOCIt analysis was started by selecting the “Start” button.  As soon as “Start” was 
selected, the running analysis time was displayed near “Time Elapsed.” There was a blue 
progress bar that tracked the analysis.  Once the analysis was completed, the NOCIt output 
and results files were exported and saved to the directory that was specified in the “Add 
Batch Run” window. 
2.2.  Developmental Validation 
2.2.1.  Methods 
2.2.1.1.  Calibration File Generation 
 Four calibration sample sets were used during the validation process: two, distinct, 
AmpFlstr® Identifiler® Plus sample sets, one GlobalFiler® sample set and one PowerPlex® 
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16 HS sample set.  A validation previously completed determined the minimum number of 
samples in the calibration sample set to be 50 (80).  The format of the files used for 
calibration followed the description in Section 2.1.1.2, unless manipulated to create new 
files for testing the limits and capabilities of the Calibrate tab. 
 One Identifiler® Plus sample set was composed of 625 pristine single source 
samples from 69 individuals.  The samples were amplified using AmpFlstr® Identifiler® 
Plus (29 cycles) at target masses ranging from 0.008 to 1 ng.  All samples were injected 
for 10 seconds (s) on the Applied Biosystems® 3130 Genetic Analyzer (Applied 
Biosystems®, Carlsbad, CA) and analyzed with GeneMapper® ID-X at 1 RFU.  Spikes, 
dissociated dye, pull-up, complex pull-up and minus A artifacts were manually removed 
during analysis as described in (81).  The data were exported and saved as a CSV. 
The second Identifiler® Plus sample set was composed of 2632 pristine and 
degraded single source samples from 50 individuals.  The samples were amplified using 
AmpFlstr® Identifiler® Plus (28 cycles) at target masses ranging from 0.008 to 0.73 ng.  All 
samples were injected for 10 s on the Applied Biosystems® 3130 Genetic Analyzer and 
analyzed with GeneMapper® ID-X at 1 RFU.  Only spikes and dissociated dye artifacts 
were manually removed during analysis.  The data were exported and saved as a CSV. 
The GlobalFiler® sample set was composed of 2526 pristine and degraded single 
source samples from 50 individuals.  The samples were amplified using GlobalFiler® (29 
cycles) at target masses ranging from 0.003 to 1.1 ng.  All samples were injected for 15 s 
on the Applied Biosystems® 3500 Genetic Analyzer (Applied Biosystems®, Carlsbad, CA) 
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and analyzed with GeneMapper® ID-X at 1 RFU.  Only spikes and dissociated dye artifacts 
were manually removed during analysis.  The data were exported and saved as a CSV. 
The PowerPlex® 16 HS sample set was composed of 239 pristine single source 
samples from 69 individuals.  The samples were amplified using PowerPlex® 16 HS (32 
cycles) at target masses ranging from 0.008 to 1 ng.  All samples were injected for 10 s on 
the Applied Biosystems® 3130 Genetic Analyzer and analyzed with GeneMapper® ID-X at 
1 RFU.  Spikes and dissociated dye artifacts were manually removed during analysis.  The 
data were exported and saved as a CSV. 
2.2.1.2.  Sample File Generation 
Four sample sets were used during the validation process: two, distinct, AmpFlstr® 
Identifiler® Plus sample sets, one GlobalFiler® sample set and one PowerPlex® 16 HS 
sample set.  The number and types of samples in each set was dependent on availability.  
The format of the files followed the description in Section 2.1.3.7, unless manipulated to 
create new files for testing the limits and capabilities of the NOCIt tab.   
One Identifiler® Plus sample set was composed of 356 samples from 69 individuals.  
These cell types were combined to generate a series of 1- to 5- contributor samples at 
various contributor ratios, described in (80).  The samples were amplified using AmpFlstr® 
Identifiler® Plus (29 cycles) at target masses ranging from 1 to 0.008 ng.  All samples were 
injected for 10 s on the Applied Biosystems® 3130 Genetic Analyzer and analyzed with 
GeneMapper® ID-X at 1 RFU.  Spikes, dissociated dye, pull-up, complex pull-up and 
minus A artifacts were manually removed during analysis.  The data were exported and 
saved as a CSV. 
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Table 2.  Summary of the first Identifiler® Plus sample set used to validate NOCIt. 
NOC 1 2 3 4 5 TOTAL 
Number 
Prepared 
 
47 123 70 46 70 
356 Total Template 
Mass (ng) 
 
0.25-
0.0078 
1- 
0.0078 
0.59- 
0.0078 
0.25- 
0.0078 
0.25- 
0.0078 
Contributor 
Ratio 
N/A 1:1- 
1:99 
1:1:1- 
1:9:9 
1:1:1:1- 
1:9:9:1 
1:1:1:1:1- 
1:9:9:9:1 
 
A total of 759 pristine, degraded and differentially degraded samples from 50 
individuals comprised the second Identifiler® Plus sample set.  These cell types were 
combined to generate a series of 1- to 5- contributor samples at various contributor ratios, 
described in (82).  The samples were amplified using AmpFlstr® Identifiler® Plus (28 
cycles) at target masses ranging from 0.75 to 0.0078 ng.  All samples were injected for 10 
s on the Applied Biosystems® 3130 Genetic Analyzer and analyzed with GeneMapper® ID-
X at 1 RFU.  Spikes and dissociated dye artifacts were manually removed during analysis.  
The data were exported and saved as a CSV. 
Table 3.  Summary of the second Identifiler® Plus sample set used to validate NOCIt. 
NOC 1 2 3 4 5 TOTAL 
Number 
Prepared 
 
78 180 166 180 155 
759 Total Template 
Mass (ng) 
 
0.5-
0.0078 
0.75-
0.03 
0.75- 
0.045 
0.75- 
0.06 
0.75- 
0.075 
Contributor 
Ratio 
N/A 1:1- 
1:9 
1:1:1- 
1:9:9 
1:1:1:1- 
1:9:9:1 
1:1:1:1:1- 
1:9:9:9:1 
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The GlobalFiler® sample set was composed of 815 pristine, degraded and 
differentially degraded samples from 50 individuals.  These samples were combined to 
generate a series of 1- and 5- contributor samples at various contributor ratios, which are 
described in (82).  The samples were amplified using GlobalFiler® (29 cycles) at target 
masses ranging from 0.75 to 0.0078 ng.   All samples were injected for 15 s on the Applied 
Biosystems® 3500 Genetic Analyzer analyzed with GeneMapper® ID-X at 1 RFU.  Spikes 
and dissociated dye were manually removed during analysis.  The data were exported and 
saved as a CSV. 
Table 4.  Summary of the GlobalFiler® sample set used to validate NOCIt. 
 
NOC 1 2 3 4 5 TOTAL 
Number 
Prepared 
 
145 176 162 176 156 
815 Total Template Mass (ng) 
 
0.5-
0.0078 
0.75-
0.03 
0.75- 
0.045 
0.75- 
0.06 
0.75- 
0.075 
Contributor 
Ratio 
N/A 1:1- 
1:9 
1:1:1- 
1:9:9 
1:1:1:1- 
1:9:9:1 
1:1:1:1:1- 
1:9:9:9:1 
 
The PowerPlex® 16 HS sample set was composed of 155 pristine samples from 69 
individuals.  These cell types were combined to generate a series of 1- and 5- contributor 
samples at various contributor ratios, which are described in (80)Error! Reference source 
not found..  The samples were amplified using PowerPlex® 16 HS (32 cycles) at target 
masses ranging from 0.5 to 0.008 ng.  All samples were injected for 10 s on the Applied 
Biosystems® 3130 Genetic Analyzer and analyzed with GeneMapper® ID-X at 1 RFU.  
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Spikes, dissociated dye, pull-up, complex pull-up and minus A artifacts were manually 
removed during analysis.  The data were exported and saved as a CSV. 
Table 5.  Summary of the PowerPlex® 16 HS sample set used to validate NOCIt. 
NOC 1 2 3 4 5 TOTAL 
Number 
Prepared 
 
76 20 19 20 20 
155 Total Template Mass (ng) 
 
0.5-
0.0078 
0.25-
0.0156 
0.5- 
0.05 
0.25- 
0.0625 
0.25- 
0.0625 
Contributor 
Ratio 
N/A 1:1- 
1:19 
1:1:1- 
1:9:9 
1:1:1:1- 
1:9:9:1 
1:1:1:1:1- 
1:9:9:9:1 
 
2.2.1.3.  Frequency File Generation 
 A total of nine populations were used during the validation of NOCIt.  Three 
population files were created for each amplification kit.  These populations were African 
American, Caucasian and Hispanic.  The allele frequency data were obtained from the 
AmpFlstr® Identifiler® Plus User’s Guide, the PowerPlex® 16 HS Technical manual and 
the GlobalFiler® User’s Guide (70, 72, 74).  Each file was formatted according to the 
description defined in Section 2.1.3.1.   
2.2.1.4.  Testing Methodology 
 The standard operating procedure for the validation of NOCIt was written in 
accordance with the General Principles of Software Validation, Version 2.0 developed by 
the Center for Devices and Radiological Health (36).  NOCIt was tested using the data sets 
described in Section 2.2.1.1, Section 2.2.1.2 and Section 2.2.1.3.  Figure 15 is a flowchart 
depicting the general steps used during the testing and validation of NOCIt. 
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Figure 15.  General software testing procedure. 
First, the user requirements were defined and used to determine if NOCIt was fit-
for-use.  Each user requirement was given a test case ID that was assigned sequentially 
from 1.  A risk assessment was then performed to assign the criticality level and the 
complexity level of the software.  The assessment categorized NOCIt as both critical and 
complex; critical because of its ability to substantially influence forensic DNA 
interpretation, statistical conclusions and the accuracy of the results, and complex because 
it contained many lines of code, complex algorithms and interconnected modules.  Due to 
its classification as complex and critical, NOCIt software validation testing included: 1) 
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functional; 2) reliability; and 3) regression testing.  One or more of these types of tests were 
used to analyze the defined user requirements.   
Following the design of the test, acceptance criteria were defined.  Acceptance 
criteria were the expected responses from NOCIt and were based on the user requirements 
and test type.  These criteria were evaluated when determining whether NOCIt either 
passed or failed a given test.  However, failing a single test does not necessarily mean the 
software is invalid.  Failure of the software to meet the pre-defined expectations can be 
fixed, accepted or an alternative solution can be provided.  Many minor failures or few 
critical failures, however, may lead the user to conclude that the software is not fit for its 
intended use.  Ultimately, the decision to implement the software into operations is 
dependent upon pre-defined acceptance criteria and the results of the entire validation 
scheme. 
Once the test was completed, NOCIt’s response was documented and compared the 
pre-defined acceptance criteria.  A validation summary was then prepared.  This report 
detailed the steps taken to complete the test and how NOCIt responded.  This included 
images of the steps, error messages and the outputs that were observed.   
To determine whether NOCIt was valid, the validation report was reviewed in 
conjunction with the acceptance criteria.  If the software satisfied the pre-determined 
requirements, the test case was considered “By Design.” However, if NOCIt failed to meet 
the acceptance criteria, the test case was considered either “Fix Minor,” “Fix Major” or 
“Fix Critical.” The “fix” designation depended on how substantially the function being 
tested would affect NOCIt’s interpretation.  All fixes discovered during the validation 
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process were uploaded into the issue tracking and management system, JIRA, which 
assigned each fix a JIRA ID number.   
All the information detailed above was stored in a database maintained using 
Microsoft Access, depicted in Figure 16.  In addition, the database also included the 
Computer ID for the computer used to run the test and the input files used during the test 
case (kit file, calibration file, etc.)  A computer database, pictured in Figure 17, was also 
maintained on Microsoft Access.  This database described the operating system, Java 
version, processor, ram, and system type of every computer used for the validation. 
 
Figure 16.  Microsoft Access Test Case database for NOCIt validation.  Each row in the 
database describes a different test case.  The test case ID is listed in the first column.  
The “Requirement” column contains a brief description of the user requirement and the 
function location on the GUI.  The type of test is listed in the third column, “Test 
Category,” and the tester and date the tests were conducted is recorded in the fourth and 
fifth columns, respectively.  The computer used to conduct the test is recorded in the 
sixth column “Computer ID.” The last three columns describe the pre-defined acceptance 
criteria, the result of the test and fix designation. 
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Figure 17.  Microsoft Access Computer ID database for NOCIt validation.  Each row 
describes a different computer system used during validation.  The name of each 
computer, found in the “About” settings of each system, is listed in the first column.  
From left to right, the operating system, the Java version used, the processor type, the 
RAM and system type for each computer is listed. 
 After errors were corrected, a new distribution of NOCIt was released for testing.  
These new software distributions (or versions) were then used to continue the software 
validation.  In addition to new test cases, regression tests were also completed on new 
distributions.  These test were critical in detecting whether changes to the module caused 
adverse effects to other parts of the software.   
2.2.2.  Results and Discussion 
The validation process spanned 11 distributions across 325 total test cases.  Table 
6Error! Reference source not found. details how many tests were completed across each 
distribution.   
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Table 6.  Total number of tests completed on all 11 distributions tested during the 
validation of NOCIt. 
Distribution 
Number 
Distribution Date Total Test Cases 
1 092216 86 
2 093016 9 
3 101816 58 
4 102916 26 
5 110516 24 
6 111216 16 
7 111916 11 
8 112616 8 
9 120116 20 
10 121616 45 
11 022416 15 
 
The number of tests completed on each distribution was affected by the time 
between its release for testing and the release of the new distribution.  The complexity of 
tests cases completed on the distribution also affected the number of tests completed.  For 
example, many of the tests done on distribution 092216 concentrated on the functionality 
of the buttons on the GUI, such as the “Save and Close” and “Revert to Default” buttons 
in the Settings window.  These tests were completed and documented at a faster rate than 
a test that examined the effect of changing the NOCIt settings on the probability 
distributions of a batch of true 5-contributor mixtures. 
 The vast majority of the tests types used were positive tests.  Because of the 
complexities of some of the tests, they were consistent with the criteria described for 
positive and/or another functional test type.  In these instances, the standard used was to 
classify the tests as positive tests for documentation purposes.  Figure 18 shows the 
distribution of the test types across all 11 distributions.   
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Figure 18.  The distribution of the 327 n positive tests, n negative tests, n fuzz tests, n 
boundary tests and n regression tests across all 11 distributions.   
 
 Over the duration of testing, there was an increase in the proportion of tests that 
passed and met the pre-defined requirements.  In general, Figure 19 demonstrates that as 
testing ensued, a greater proportion of tests passed.  This indicates that good software 
validation practices resulted in improvements of the software GUI and functionality.  
Distribution #7, which did not follow the general trend as shown in Figure 19, had a smaller 
number of total tests completed which would have a larger effect on the proportion of tests 
that showed expected results.  Also, the testing in this distribution concentrated mainly on 
visual inconsistencies with the GUI that needed to be edited.  Distribution #9, which also 
exhibited a dip in performance, was used to test updates to the manual addition of known 
genotypes function, a major modification to NOCIt’s functionality.  Within this 
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distribution, all of the fixes were not yet completed but were still tested, resulting in a 
higher than normal failure rate. 
 
Figure 19.  Proportion of the test cases that passed across all 11 distributions.  Test types 
include positive, negative, fuzz, boundary and regression testing. 
 
 Based on the data from Figure 19, the final distribution which was used for 
continued studies had a 0% failure rate.  Though this did not mean the tool was completely 
fault free as every possible situation could not be tested, it did suggest that the system was 
fit for its intended use.  Further, these data suggest that NOCIt is robust and successfully 
completed interpretations from data generated from two distinct capillary electrophoresis 
systems; three STR multiplex kits; multiple population groups; multiple processors; and 
different users. 
2.3.  Reproducibility Study 
 After ensuring the GUI was functioning accurately and reliably, the next step was 
to validate the NOCIt settings for optimal use.  The goal was to elucidate the optimal 
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combination of settings that would maximize reproducibility without compromising 
accuracy.  Since the more stringent settings resulted in longer analysis times, it was also 
important to consider the time taken for each analysis along with the reproducibility and 
accuracy. 
2.3.1.  Methods 
2.3.1.1.  Calibration File Generation 
Two calibration sample sets were used during the reproducibility testing: one 
AmpFlstr® Identifiler® Plus sample set and one PowerPlex® 16 HS sample set.  The format 
of the files used for calibration followed the description in Section 2.1.1.2. 
 The Identifiler® Plus sample set was composed of 2505 pristine and degraded single 
source samples from 50 individuals.  The samples were amplified using AmpFlstr® 
Identifiler® Plus (28 cycles) at target masses ranging from 0.008 to 0.5 ng.  All samples 
were injected for 20 s on the Applied Biosystems® 3130 Genetic Analyzer and analyzed 
with GeneMapper® ID-X at 1 RFU.  Spikes and dissociated dye were manually removed 
during analysis.  The remaining artifacts were removed using an automated VBA script 
(82).  The data were exported and saved as a CSV. 
The PowerPlex® 16 HS sample set was composed of pristine single source samples 
from 69 individuals.  The samples were amplified using PowerPlex® 16 HS (32 cycles) 
ranging from 0.008 to 1 ng.  All samples were injected for 10 s on the Applied Biosystems® 
3130 Genetic Analyzer and analyzed with GeneMapper® ID-X at 1 RFU.  Spikes and 
dissociated dye were manually removed during analysis.  The remaining artifacts were 
removed using an automated VBA script (82).The data were exported and saved as a CSV. 
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2.3.1.2.  Sample File Generation 
Two sample sets were used during reproducibility testing: one AmpFlstr® 
Identifiler® Plus sample set and one PowerPlex® 16 HS sample set.  The number and types 
of samples in each set was dependent on availability.  The format of the files used for 
calibration followed the description in Section 2.1.3.7. 
The Identifiler® Plus sample set consisted of 827 pristine, degraded and 
differentially degraded samples from 50 individuals.  These cell types were combined to 
generate a series of 1- to 5- contributor samples at various contributor ratios, described in 
(82)Error! Reference source not found..  The samples were amplified using AmpFlstr® 
Identifiler® Plus (28 cycles) at target masses ranging from 0.75 to 0.0078 ng.  All samples 
were injected for 20 s on the Applied Biosystems® 3130 Genetic Analyzer analyzed with 
GeneMapper® ID-X.  Spikes and dissociated dye were manually removed during analysis.  
The remaining artifacts were removed using an automated VBA script (82).  The data were 
exported and saved as a CSV. 
Table 7.  Summary of the Identifiler® Plus sample set used to validate the NOCIt settings. 
NOC 1 2 3 4 5 TOTAL 
Number 
Prepared 
 
150 182 165 169 161 
827 Total Template Mass (ng) 
 
0.5-
0.0078 
0.75-
0.03 
0.75- 
0.045 
0.75- 
0.06 
0.75- 
0.075 
Contributor 
Ratio 
N/A 1:1- 
1:9 
1:1:1- 
1:9:9 
1:1:1:1- 
1:9:9:1 
1:1:1:1:1- 
1:9:9:9:1 
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 The PowerPlex® 16 HS sample set was composed of 155 pristine samples from 69 
individuals.  These cell types were combined to generate a series of 1- to 5- contributor 
samples at various contributor ratios, described in (80)Error! Reference source not 
found..  The samples were amplified using PowerPlex® 16 HS (32 cycles) at target masses 
ranging from 0.5 to 0.0078 ng.  All samples were injected for 10 s on the Applied 
Biosystems® 3130 Genetic Analyzer and analyzed with GeneMapper® ID-X at 1 RFU.  
Spikes and dissociated dye were manually removed during analysis.  The remaining 
artifacts were removed using an automated VBA script (82).  The data were exported and 
saved as a CSV. 
Table 8.  Summary of the PowerPlex® 16 HS sample set used to validate the NOCIt 
settings. 
NOC 1 2 3 4 5 TOTAL 
Number 
Prepared 
 
76 20 19 20 20 
155 Total Template Mass (ng) 
 
0.5-
0.0078 
0.25-
0.0156 
0.5- 
0.05 
0.25- 
0.0625 
0.25- 
0.0625 
Contributor 
Ratio 
N/A 1:1- 
1:19 
1:1:1- 
1:9:9 
1:1:1:1- 
1:9:9:1 
1:1:1:1:1- 
1:9:9:9:1 
 
2.3.1.3.  Frequency File Generation 
A total of two populations were used during the validation of the NOCIt settings.  
One Caucasian population was created for each amplification kit used.  The allele 
frequency data were provided by the AmpFlstr® Identifiler® Plus User’s Guide and the 
PowerPlex® 16 HS Technical manual (70, 74).  Each file was formatted according to the 
description in Section 2.1.3.1.   
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2.3.1.4.  Testing Methodology 
 Initial NOCIt settings, termed Condition 1 and Condition 2, were tested and 
demonstrated reasonable performance (data not shown).  However, in order to implement 
NOCIt for the long-term, a systematic study of the effects of the parameters are required.  
To determine the optimal value for the Number of Samples in Batch and the Multiplicative 
Factor, Condition 3 and Condition 4 were tested.  Each condition was tested in triplicate 
for both sample sets.  The parameters are listed in Table 9. 
 
Table 9.  NOCIt settings for Condition 3 and Condition 4 tested during the 
reproducibility testing. 
 
NOCIt Parameters Parameter Value 
Condition 3 Condition 4 
Levels for Mixture Ratios 12 12 
Standard Error Tolerance 0.05 0.05 
Refinement Time Limit 7200 7200 
Number of Samples in 
Batch 4000 3000 
Multiplicative Factor 3.0 4.0 
Maximum Number of 
Samples in Batch 175 000 175 000 
 
 One calibration project using the calibration sample set described in Section 2.3.1.1 
was created for both kits.  The filter function was left unchecked as all known artifacts 
were manually removed at the analysis stage (see Section 2.3.1.1).  This calibration project 
was used for each run.  The samples were added in one batch with the filter function 
unchecked, as all known artifacts were removed at the analysis stage (see Section 2.3.1.2).  
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The Caucasian population was utilized in this phase.  This was repeated three times for 
each sample set.  An AT of 1 RFU was used at all loci tested. 
2.3.2.  Results and Discussion 
 To assess the variation between the APPs assigned to the NOC of a sample for each 
condition and data set, the range of the maximum a posteriori probabilities (MAP) across 
all three replicates was plotted against the largest of the three MAP values.  For example, 
Table 10 shows the NOCIt results for a pristine, 5-contributor, Powerplex® 16 HS sample.  
The range of the MAP would be the difference between 9.92E-1 and 9.89E-1.  The largest 
of the three MAP is 9.92E-1.  The data point for this sample would then be 9.92E-1, 3.00E-
3. 
Table 10.  Summary of a posteriori probabilities assigned to a pristine 5-contributor 
PP16 sample when tested in triplicate. 
 
Number of 
Contributors Replicate 1 Replicate 2 Replicate 3 
0 0 0 0 
1 0 0 0 
2 7.36E-154 4.52E-154 8.89E-154 
3 9.92E-1 9.89E-1 9.92E-1 
4 7.64E-3 1.02E-2 8.19E-3 
5 7.40E-6 7.40E-6 9.87E-6 
 
Figure 20 is a scatter plot of the MAP range versus the largest MAP for the 
PowerPlex® 16 HS test set.  Both conditions appeared to be similar.  Most of the data 
concentrated along or near the x = 1 line.  The arbitrarily chosen line of y = 0.01 allowed 
for comparisons to be made between both conditions.  The data points above this line 
signified samples that were classified as having large variations between the APPs 
52 
assigned, which denotes variable results between runs.  The plot created for Condition 3 
demonstrated that 28% of the runs exceeded y = 0.01, while Condition 4 resulted in 25% 
of the runs exceeding y = 0.01, indicating that Condition 4 for the PowerPlex® 16 HS 
samples resulted in a larger number of reproducible runs.  Most of the data points above 
the y = 0.01 threshold in both conditions corresponded to the same samples and consisted 
of mainly 3-, 4- and 5- contributor samples with minor template masses below 0.03 ng.  
Therefore, there may be some correlation between the complexity of the sample and its 
reproducibility.  Additionally, many samples in both conditions appear to congregate 
between y > 0.01 and x > 0.99.  Seven samples using Condition 3 had a Range MAP greater 
than 0.01 and the largest of the 3 MAPs greater than 0.99.  These samples were 1-, 3-, 4- 
and 5 - contributor samples with minor contributor masses ranging from 0.02 to 0.5 ng.  
When using Condition 4, nine samples fell into the category described.  These samples 
were 1-, 3-, 4- and 5 - contributor samples that were somewhat complex.  The minor 
contributor template masses ranged from 0.003 to 0.5 ng.  Only three samples had a Range 
MAP greater than 0.01 and the largest of the three MAPs greater than 0.99 in both 
conditions. 
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Figure 20.  NOCIt PowerPlex® 16 HS reproducibility results using A) Condition 3 and 
B) Condition 4 for (♦) 1 - Contributor, (n) 2 - Contributor, () 3 - Contributor, (Ï) 4 
– Contributor and (Û) 5 - Contributor samples. 
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Based on the accuracies depicted in Figure 21, neither condition appeared to be 
significantly more accurate than the other.  When analyzing samples with APP > 50% for 
the NOCtrue (i.e., the true number of contributors), the accuracies were the same.  Also, 
when analyzing > 1% APP for the NOCtrue, the accuracies were the same when the mass 
of the minor contributor was larger than 0.03 ng.  Condition 3 was more accurate only for 
samples of > 2 contributors with a minor template mass > 0.03 ng. 
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Figure 21.  A heat map for the NOCIt PowerPlex® 16 HS accuracy results for 1) 
Condition 3 and 2) Condition 4.  1a) and 2a) accuracies were calculated when NOCtrue 
was assigned a probability at or greater than 1%.  1b) and 2b) accuracies were calculated 
when NOCtrue was assigned a probability at or greater than 50%. 
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Figure 22 shows the reproducibility results for the AmpFlstr® Identifiler® Plus data 
set.  Both conditions demonstrated similar accuracies but did show differences in their 
reproducibility.  Similar to the PowerPlex® 16 HS samples, most of the data concentrated 
along or near the x = 1 line.  The plot created for Condition 3 demonstrated that 27% of the 
runs exceeded y = 0.01, while Condition 4 resulted in 32% above the y = 0.01 line, 
indicating that Condition 3 for the AmpFlstr® Identifiler® Plus samples resulted in a larger 
number of reproducible runs.  Many of the data points above y = 0.01 in both conditions 
corresponded to the same samples.  Most of the samples found above that line were higher-
order mixtures; however, less than half of those had a minor template mass of below 0.03 
ng for both conditions.  Therefore, no conclusion can be made regarding the correlation 
between the reproducibility and the complexity of the samples.   
Of the 827 total samples, 56 samples tested using Condition 3 had a Range MAP 
greater than 0.01 and the largest of the three MAPs greater than 0.99.  These samples were 
complex, 3-, 4- and 5- contributor, samples with minor contributor masses ranging from 
2.8E-8 to 0.09 ng (averaging 0.03 ng).  The majority of these samples were uniformly 
degraded, while 9% were differentially degraded and 5% were pristine.  When using 
Condition 4, 78 samples fell into the category described.  These samples were complex, 3-
, 4- and 5- contributor samples with a similar minor contributor template range as Condition 
3 (averaging 0.04 ng).  Similarly, the majority of these samples were uniformly degraded, 
while 6% were differentially degraded and 12% were pristine.   
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Figure 22.  NOCIt  AmpFlstr® Identifiler® Plus reproducibility results using A) Condition 
3 and B) Condition 4 for (♦)1 - Contributor, (n) 2 - Contributor, () 3 - Contributor, (Ï) 
4 – Contributor and (Û) 5 - Contributor samples. 
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Similar to the accuracies observed in the PowerPlex® 16 HS sample set, neither 
condition appeared to render differences in accuracy rates.  As shown in Figure 23, when 
exploring samples that exhibit APPs > 50% for the NOCtrue, Condition 3 was more accurate 
for 4- and 5- contributor mixtures.  Also, when analyzing > 1% APP for the NOCtrue, the 
accuracies were similar when the mass of the minor contributor was larger than 0.03 ng.  
Only with samples containing > 2 contributors with a minor template mass > 0.03 ng was 
Condition 3 shown to be more accurate. 
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Figure 23.  NOCIt AmpFlstr® Identifiler® Plus accuracy results for A) Condition 3 and 
B) Condition 4.  1a) and 2a) accuracies were calculated when NOCtrue was assigned a 
probability at or greater than 1%.  1b) and 2b) accuracies were calculated when NOCtrue 
was assigned a probability at or greater than 50%. 
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3.  Quantitation – Variability Study 
3.1.  Methods  
3.1.1.  Preparation of Test Samples 
 The samples used to investigate the source of variation in qPCR methods were 
generated by diluting a solution of 100 ng/µL THP DNA standard.  This was accomplished 
by adding 5 µL of THP to 95 µL of Tris-ethylenediaminetetraacetic (EDTA) acid (TE) 
(10nM Tris, 0.1 mM EDTA) to create dilution d0 (5 ng/ µL).  Four ten-fold serial dilutions 
followed by adding 50 µL of each successive sample to 450 µL of TE.  Each successive 
dilution was labelled d1 to d4. 
3.1.2.  Quantitative Real-Time Polymerase Chain Reaction 
3.1.2.1.  Quantifiler® Duo Method 
 Quantifiler® Duo calibration standards ranging from 50 to 0.023 ng/µL were 
prepared in accordance with the user’s manual (42, 60).  The 200 ng/µL stock standard was 
first diluted to 50 ng/µL by adding 10 µL of the stock to 30 µL of the dilution buffer 
provided.  Seven threefold serial dilutions followed.  Each standard of known concentration 
was generated by adding 10 µL of each previously diluted standard to 20 µL buffer to 
create eight standard dilutions.  These standards were run in duplicate in the first two 
columns of a 96-well microtiter plate, in addition to a sample of dilutions d1 and d2 and 
six replicates of dilutions d3 and d4.  The amplification parameters used were in accordance 
with the manufacturer’s recommended conditions.  Standard curves were generated for the 
human RPPH1 targets.  This was repeated using four additional 96-well runs.   
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3.1.2.2.  Quantifiler® Trio Method 
 Quantifiler® Trio calibration DNA standards ranging from 50 to 0.05 ng/µL were 
created according to the user’s manual (22, 61).  The 100 ng/µL stock standard was first 
diluted to 50 ng/µL by adding 10 µL of the stock to 10 µL of the Quantifiler® THP DNA 
dilution buffer provided.  Four tenfold dilution serial dilutions followed by adding 10 µL 
of each dilution to 90 µL buffer to create five standard dilutions.  These standards were run 
in duplicate in the first two columns of a 96-well microtiter plate, in addition to a sample 
of dilutions d1 and d2 and six replicates of dilutions d3 and d4.  The amplification 
parameters used were in accordance with the manufacturer’s recommended conditions.  
Standard curves were generated for the human (large and small autosomal) targets.  This 
was repeated using four additional 96-well runs.   
3.1.2.3.  Sample Concentration Calculations 
 Two methods of determining the sample concentration were used: 1) the 
Experimental Method which involved using a per annum validation calibration curve and 
2) the Recommended Method described in the Quantifiler® PCR manuals.  The former did 
not require reserving rows for the calibration DNA standards with each assay and depended 
on the internal positive control (IPC) as an indicator of PCR efficiency and reproducibility, 
while the latter consists of a duplicate calibration generated for every qPCR assay(60, 61).  
In total, there was a single validated curve using the Experimental Method and five curves 
using the Recommended Method (per target, per qPCR per kit).   
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3.1.3.  Digital Polymerase Chain Reaction 
3.1.3.1.  Variability Study 
 To compare the variation between quantification methods, the dPCR method for 
determining the quantity of an unknown sample was examined.  Dilution d1, d2, d3 and d4 
were loaded onto chips using the QuantStudio™ 3D Digital PCR Chip Loader and 
amplified using the ProFlex™ 2x Flat PCR System.  The amplification program was as 
follows: 1 cycle at 96o C for 10 minutes; 39 cycles at 60o C for 2 minutes and 98o C for 30 
seconds; 1 cycle at 60o C for 2 minutes and 10o C for infinity.  The results were imaged on 
the QuantStudio™ 3D Digital PCR Instrument and analyzed using the QuantStudio™ 3D 
AnalysisSuite™ software, according to the manufacturer’s recommended protocol (52, 
53).  The unit of output using this instrument was in copies of DNA per µL and required 
the conversion to ng/µL for direct comparisons between the dPCR and qPCR methods.  
This procedure was repeated four times.   
3.1.3.2.  Contamination Study 
 To determine whether the signal observed in the negative control chip was an 
indication of contamination or instrument noise, five negative chips were loaded and 
immediately imaged.  The chips were not amplified by the ProFlex™ 2x Flat PCR System. 
3.2.  Results and Discussion 
The study performed by Grgicak et al., revealed that using one external validated 
curve demonstrated less variability between dilution series than the method recommended 
by the manufacturer.  This resulted in a reduced impact on the calibration curve stability 
(40).  Therefore, the work done in this study attempted to examine how both the 
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Experimental Method and the Recommended Method led to qPCR variability between kit 
type and instrument. 
3.2.1.  qPCR Variability  
 The coefficient of variation for the replicates of d1, d2, d3 and d4 was calculated 
and plotted as shown in Figure 24 and Figure 25 for the Quantifiler® Duo and Quantifiler® 
Trio data sets, respectively.  Figure 24 demonstrates a consistent increase in variation as 
the dilutions increased.  One inconsistency observed in the data was a lower variability in 
dilution d4 than d3.  Also, d4 expressed lower variability when using the Recommended 
Method.  Dilution d4 experienced a 73% false negative rate which could be responsible for 
the smaller coefficient of variation for both methods.  Additionally, a two-tailed T-test 
failed to show significant differences between the concentration values for d4. 
  
Figure 24.  Variation between the 5 replicates of d1 and d2 and 30 replicates of d3 and 
d4 using the the Quantifiler® Duo (♦) Experimental Method and (n) Recommended 
Method. 
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In the Quantifiler® Trio data depicted in Figure 25, results from both  the small and 
large autosomal targets were plotted.  Similar to the Quantifiler® Duo data, there was a 
consistent increase in variation as the dilution increased.  Since the false negative rates for 
both the small and large targets were 7% and 0%, respectively, as opposed to the 73% seen 
in Quantifiler® Duo, d4 had the largest variation, as expected.   
  
Figure 25.  Variation between the 5 replicates of d1 and d2 and 30 replicates of d3 and 
d4 using the the Quantifiler® Trio (♦) Experimental Method (large autosomal target), 
(n) Recommended Method (large autosomal target), ( ) Experimental Method (small 
autosomal target) and ( ) Recommended Method (small autosomal target). 
 
Unlike Quantifiler® Duo, the Quantifiler® Trio data showed no particular trend in 
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dilutions.  Therefore, the Quantifiler® Trio assay appeared to be less susceptible to 
inconsistencies associated with low copy numbers.  This may be explained by the use of 
multicopy loci as targets for PCR in this assay.   
3.2.2.  dPCR Variability 
 The results depicted in Figure 26 using QuantStudio™ continued to demonstrate 
that the more dilute samples were more susceptible to variability in concentration.  The 
variability between the two more concentrated samples, d1 and d2, were consistent with 
the Experimental Method observed in Figure 24 for those same dilutions.  As the samples 
became more dilute, the dPCR method using QuantStudio™ exhibited larger variation, 
exceeding the Quantifiler® Duo and Trio values in Figure 24 and Figure 25, respectively.   
This dPCR assay, which was similar in assay design to Quantifiler® Duo with the 
use of a single copy RPPH1 target, was prone to underestimations of the concentration 
when compared to the values calculated using both the Quantifiler® Duo and Quantifiler® 
Trio assays.   
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Figure 26.  Variation between the 5 replicates of d1, d2, d3, d4, the negative control 
(NEG) and the non-amplified negative (NO AMP) using the the QuantStudio™ 3D 
Digital PCR Instrument. 
 
3.2.3.  Contamination Study 
 The d3 and d4 concentrations exhibited overlapping concentrations between 
replicates.  As depicted in Figure 27, there was signal detected for the negative control 
when using the QuantStudio™ 3D Digital PCR instrument.  The values for the negative 
also could not be resolved from the values calculated for the d3 and d4 dilutions.  To ensure 
that the values being observed were not an indication of false positive DNA contamination 
but a reflection of instrument noise being observed, five unamplified negative chips were 
loaded and imaged.  It was hypothesized that if the chips were not amplified and signal 
was observed, that this was indicative of instrument or assay noise rather than drop in. 
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3.2.4.  False Negative Rates 
 Because of the noise associated with dPCR, there were no instances of false 
negative rates.  However, qPCR did show various instances of false negative rates between 
the Quantifiler® Duo and Quantifiler® Trio kits.  These rates were analyzed using 30 
replicates of d3 and d4, as shown in Figure 27. 
  
Figure 27.  False negative rates of () 0.005 ng/ µL dilution, d3, and ()0.0005 ng/ µL 
dilution, d4, across the Quantifiler® Duo (QuantDuo) and Quantifiler® Trio (QuantTrio) 
quantification kits used.  LA (large autosomal target).  SA (short autosomal target). 
 
The tenfold dilution from 0.005 to 0.0005 ng/ µL largely impacted the false 
negative rate in the Quantifiler® Duo data.  Dilution d4 experienced a 66% larger rate of 
false negatives than d3.  On the other hand, the Quantifiler® Trio large autosomal target did 
produce measurable signal in all 30 replicates.  The short autosomal target exhibited no 
false negatives in its d3 dilution and a very low rate of 7% in its d4 dilution. 
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Because of the single copy locus in Quantifiler® Duo, there is an increased 
probability of allele drop out due to sampling effects.  The use of a multicopy locus in 
Quantifiler® Trio improved the efficiency and sensitivity of the assay. 
4.  Conclusions 
4.1.  NOCIt Validation 
 Even though it was impossible to test every possible function, scenario and 
combination of scenarios that would result in an error in NOCIt, the protocol designed in 
accordance with the guidance by the Center for Devices and Radiological Health proved 
to be thorough during the validation of NOCIt (36).  With an overall improvement of the 
GUI and sample interpretation over eleven software distributions, the developmental 
validation was successful.  Due to the large number of corrective actions taken to improve 
NOCIt’s functionality, it supports the notion that software tools, even outside the discipline 
of digital forensics, require developmental software validation before implementation. 
4.2.  NOCIt Reproducibility  
Comparison of Condition 3 and Condition 4 on the AmpFlstr® Identifiler® Plus and 
the PowerPlex® 16 HS sample sets suggests that the results were not significantly different.  
While the PowerPlex® 16 HS samples appeared to be slightly more reproducible with the 
settings associated with Condition 4, the Identifiler® Plus samples were more reproducible 
with Condition 3.  Thus, in general, neither condition outperformed the other. 
In terms of accuracy, PowerPlex® 16 HS results were unaffected by the change in 
the settings.  However, Identifiler® Plus showed almost a twofold improvement for 5-
contributor samples with minor template masses below 0.03 ng when Condition 3 settings 
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were utilized as opposed to Condition 4.  This improvement, on the other hand, is less 
significant if the best failure rate is 90%.   
One characteristic of note was the time taken for samples to run on Condition 3 and 
Condition 4.  Overall, Condition 3 was the faster of the two methods, taking nearly two 
days less to analyze the entire batch of 827 samples.  Therefore, with regards to Condition 
4, the slight improvement in reproducibility for PowerPlex® 16 HS and the small 
improvement in accuracy of a negligible subset of the Identifiler® Plus samples coupled 
with run-time considerations suggest that Condition 3 settings are viable for NOC 
determinations. 
4.3.  Quantification 
Comparison of the Experimental Method (using one validated calibration curve) 
and the manufacturer’s Recommended Method (a calibration curve created for every 
quantification run) exhibits substantive differences.  The Experimental Method appeared 
to show less variability when using Quantifiler® Duo for high-template masses.  However, 
when applied to Quantifiler® Trio, both methods showed similar variabilities.  Therefore, 
the source of the variation includes both stochastic effects associated with pipetting and 
whether the targets are single or multicopy.  Further, the dPCR method of absolute 
quantification shows less variability than the Quantifiler® Duo results. 
Previous to studies by Campomenosi et al.  and Dong et al.  have demonstrated that 
dPCR tended to suggest lower quantities of the DNA than qPCR-based assays (63, 83).  In 
addition, though dPCR demonstrates greater precision and reproducibility in a clinical 
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setting (65), it appears that assay design and the amplification of multicopy targets has 
more of an effect on quantification results than the method type itself.   
Though the Experimental Method did not outperform the traditional Recommended 
Method, the Recommended Method requires more frequent purchasing of reagents and 
additional labor.  Therefore, based on this evidence, the use of a historic external calibration 
coupled with multicopy qPCR-based assays are a viable means to quantify DNA in the 
low- and high-copy regimes. 
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